People: Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

18 Oct 2019
Change (% chg)

$-0.02 (-0.50%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Bigham, Michael 

Mr. Michael F. Bigham serves as Independent Director of the Company. has served as a member of our Board of Directors since September 2016. Mr. Bigham was appointed Chief Executive Officer and Chairman of the board of directors of Paratek Pharmaceuticals, Inc. in October 2014. Mr. Bigham has more than 25 years of senior leadership experience in the biopharmaceutical industry. From 2003 to 2013, he was a General Partner at Abingworth LLP, a leading international investment group dedicated to life sciences and healthcare. From 2014 to 2018, he served as an Executive Partner at Abingworth LLP. He currently serves on the boards of Paratek Pharmaceuticals and Adamas Pharmaceuticals, and in the past has held several directorships, including at Avila Therapeutics (where he was also the founding Chairman and CEO), Magellan Biosciences, Portola Pharmaceuticals, Supernus Pharmaceuticals, Inmediata (Chairman) and Valeritas. Mr. Bigham was formerly Vice Chairman of Corixa Corporation, a publicly-traded biotechnology company, and was President and Chief Executive of Coulter Pharmaceuticals, a publicly-traded oncology company, until it merged into Corixa. Previously, he was an early employee at Gilead Sciences where he served in various capacities, including Executive Vice President of Operations and Chief Financial Officer. Before joining Gilead, Mr. Bigham was a Partner at Hambrecht & Quist where he became Co-Head of Healthcare Investment Banking. Mr. Bigham received his B.S. from the University of Virginia and qualified as a C.P.A. before completing his M.B.A. at Stanford University. We believe Mr. Bigham’s extensive experience on the boards of and in management positions with biopharmaceutical companies, including publicly-traded companies, qualifies him to serve on our Board of Directors.

Basic Compensation

Total Annual Compensation, USD 52,750
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 168,235
Fiscal Year Total, USD 220,985

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --